PofoliaShared via Pofolia

CA A Cancer Journal for Clinicians· 2016Q1

2016 US lymphoid malignancy statistics by World Health Organization subtypes

Lauren R. Teras, Carol DeSantis, James R. Cerhan, Lindsay M. Morton et al.

Short summary

In 2016, 136,960 new lymphoid neoplasms were expected in the US, with incidence and survival rates varying significantly by subtype and race, according to 2008 WHO classifications.

AI-generated from the title and abstract; the full text is not read.

Key points

  • Estimated 136,960 new lymphoid neoplasms in the US in 2016.
  • Incidence trends vary by subtype; precursor B-cell and plasma cell neoplasms are increasing.
  • 5-year survival rates differ widely, from 36% for peripheral T-cell lymphomas to 92% for mycosis fungoides.
  • Black men generally had the lowest survival rates across subtypes.

AI-generated from the title and abstract; the full text is not read.

Abstract

Collectively, lymphoid neoplasms are the fourth most common cancer and the sixth leading cause of cancer death in the United States. The authors provide contemporary lymphoid neoplasm statistics by subtype based on the 2008 World Health Organization classifications, including the most current US incidence and survival data. Presented for the first time are estimates of the total numbers of US lymphoid neoplasm cases by subtype as well as a detailed evaluation of incidence and survival statistics. In 2016, 136,960 new lymphoid neoplasms are expected. Overall lymphoma incidence rates have declined in recent years, but trends vary by subtype. Precursor lymphoid neoplasm incidence rates increased from 2001 to 2012, particularly for B-cell neoplasms. Among the mature lymphoid neoplasms, the fastest increase was for plasma cell neoplasms. Rates also increased for mantle cell lymphoma (males), marginal zone lymphoma, hairy cell leukemia, and mycosis fungoides. Like incidence, survival for both mature T-cell lymphomas and mature B-cell lymphomas varied by subtype and by race. Patients with peripheral T-cell lymphomas had among the worst 5-year relative survival (36%-56%, depending on race/sex), while those with mycosis fungoides had among the best survival (79%-92%). For B-cell lymphomas, 5-year survival ranged from 83% to 91% for patients with marginal zone lymphoma and from 78% to 92% for those with hairy cell leukemia; but the rates were as low as 47% to 63% for patients with Burkitt lymphoma and 44% to 48% for those with plasma cell neoplasms. In general, black men had the lowest survival across lymphoid malignancy subtypes. These contemporary incidence and survival statistics are useful for developing management strategies for these cancers and can offer clues regarding their etiology. CA Cancer J Clin 2016;66:443-459. © 2016 American Cancer Society.

The authors' abstract, as published at the source. CA A Cancer Journal for Clinicians, 2016 · DOI ↗

TakeawaysPremium
Ask the paperFree account

Continue with a free account

Ask the paper: 3 free questions a day about this paper; save it, get its citation, new summaries every day for your field. Takeaways are Premium.

Continue free on the web

Sign in with Google or Apple; no card needed. You come back to this paper.

On your phone:

Field: Pathology and Forensic Medicine

Pathology and Forensic MedicineMedicine